MA34013B1 - Inhibiteurs du virus de l'hépatite c - Google Patents

Inhibiteurs du virus de l'hépatite c

Info

Publication number
MA34013B1
MA34013B1 MA35161A MA35161A MA34013B1 MA 34013 B1 MA34013 B1 MA 34013B1 MA 35161 A MA35161 A MA 35161A MA 35161 A MA35161 A MA 35161A MA 34013 B1 MA34013 B1 MA 34013B1
Authority
MA
Morocco
Prior art keywords
present
compounds
hepatitis
virus
further relates
Prior art date
Application number
MA35161A
Other languages
Arabic (ar)
English (en)
Inventor
Yao-Ling Qiu
Ce Wang
Xiaowen Peng
Lu Ying
Hui Cao
Yat Sun Or
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44307283&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34013(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MA34013B1 publication Critical patent/MA34013B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

La présente invention concerne des composés de formule (i), et des sels pharmaceutiquement acceptables, des esters, ou des promédicaments de ceux-ci : q-g-a-l-b-w (i) qui inhibent un virus contenant de l'arn, en particulier le virus de l'hépatite c (vhc). Par conséquent, les composés de la présente invention interfèrent avec le cycle de vie du virus de l'hépatite c et sont également utiles en tant qu'agents antiviraux. La présente invention concerne en outre des compositions pharmaceutiques comprenant les composés mentionnés ci-dessus pour administration à un sujet souffrant d'une infection par le vhc. L'invention concerne en outre des procédés de traitement d'une infection par le vhc chez un sujet par administration d'une composition pharmaceutique comprenant les composés de la présente invention.
MA35161A 2010-01-25 2011-01-25 Inhibiteurs du virus de l'hépatite c MA34013B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29791810P 2010-01-25 2010-01-25
US31430410P 2010-03-16 2010-03-16
PCT/US2011/022401 WO2011091417A1 (fr) 2010-01-25 2011-01-25 Inhibiteurs du virus de l'hépatite c

Publications (1)

Publication Number Publication Date
MA34013B1 true MA34013B1 (fr) 2013-02-01

Family

ID=44307283

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35161A MA34013B1 (fr) 2010-01-25 2011-01-25 Inhibiteurs du virus de l'hépatite c

Country Status (22)

Country Link
US (1) US8785487B2 (fr)
EP (1) EP2528436A4 (fr)
JP (1) JP2013518060A (fr)
KR (1) KR20120107529A (fr)
CN (1) CN102843909A (fr)
AU (1) AU2011207492A1 (fr)
BR (1) BR112012018529A2 (fr)
CA (1) CA2787309A1 (fr)
CL (1) CL2012002057A1 (fr)
CO (1) CO6571891A2 (fr)
CR (1) CR20120397A (fr)
CU (1) CU20120110A7 (fr)
EA (1) EA201201031A1 (fr)
EC (1) ECSP12012067A (fr)
GT (1) GT201200230A (fr)
IL (1) IL221033A0 (fr)
MA (1) MA34013B1 (fr)
MX (1) MX2012008658A (fr)
PE (1) PE20130244A1 (fr)
SG (1) SG188957A1 (fr)
TN (1) TN2012000358A1 (fr)
WO (1) WO2011091417A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US8192474B2 (en) 2006-09-26 2012-06-05 Zeltiq Aesthetics, Inc. Tissue treatment methods
US20080287839A1 (en) 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
WO2009026471A1 (fr) 2007-08-21 2009-02-26 Zeltiq Aesthetics, Inc. Surveillance du refroidissement de cellules riches en lipides sous-cutanés, tel que le refroidissement du tissu adipeux
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734956B2 (ja) * 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
EP4066797A1 (fr) 2009-04-30 2022-10-05 Zeltiq Aesthetics, Inc. Dispositif d'élimination de chaleur à partir de cellules riches en lipide sous-cutanées
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PL2628481T3 (pl) 2009-06-11 2016-08-31 Abbvie Bahamas Ltd Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
CN102656160A (zh) 2009-07-16 2012-09-05 顶点制药公司 用于治疗或预防黄病毒感染的苯并咪唑类似物
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MX2012008660A (es) 2010-01-25 2013-02-26 Zeltiq Aesthetics Inc Aplicadores de uso para remover de manera no invasiva calor celulas subcutaneas ricas en lipido a traves de enfriadores de cambio de face, y dispositivos, sistemas y metodos asociados.
AU2011232331A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
EP2575819A4 (fr) 2010-06-04 2013-11-27 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US10722395B2 (en) 2011-01-25 2020-07-28 Zeltiq Aesthetics, Inc. Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5669984B2 (ja) 2011-05-18 2015-02-18 エナンタ ファーマシューティカルズ インコーポレイテッド ５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法
JP2014534206A (ja) 2011-10-17 2014-12-18 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤
PT107925A (pt) * 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2869908C (fr) * 2012-04-25 2018-02-20 Theravance Biopharma R&D Ip, Llc Inhibiteurs du virus de l'hepatite c
WO2014055069A1 (fr) * 2012-10-02 2014-04-10 Presidio Pharmaceuticals, Inc. Formes solides comprenant un inhibiteur de ns5a du vhc, compositions à base de celles-ci et leurs utilisations
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015009744A1 (fr) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Associations comprenant des dérivés de biphényle destinées à être utilisées pour le traitement du virus de l'hépatite c
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
EP4279041A3 (fr) 2014-01-31 2024-01-24 Zeltiq Aesthetics, Inc. Compositions et systèmes de traitement pour le refroidissement amélioré de tissu riche en lipides
CN104860931A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
US10675176B1 (en) 2014-03-19 2020-06-09 Zeltiq Aesthetics, Inc. Treatment systems, devices, and methods for cooling targeted tissue
USD777338S1 (en) 2014-03-20 2017-01-24 Zeltiq Aesthetics, Inc. Cryotherapy applicator for cooling tissue
US10952891B1 (en) 2014-05-13 2021-03-23 Zeltiq Aesthetics, Inc. Treatment systems with adjustable gap applicators and methods for cooling tissue
US10568759B2 (en) 2014-08-19 2020-02-25 Zeltiq Aesthetics, Inc. Treatment systems, small volume applicators, and methods for treating submental tissue
US10935174B2 (en) 2014-08-19 2021-03-02 Zeltiq Aesthetics, Inc. Stress relief couplings for cryotherapy apparatuses
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
CN105859748B (zh) * 2015-02-05 2018-06-08 爱博新药研发(上海)有限公司 多环化合物钠盐及其多晶型、制备方法及应用
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017023631A1 (fr) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US11154418B2 (en) 2015-10-19 2021-10-26 Zeltiq Aesthetics, Inc. Vascular treatment systems, cooling devices, and methods for cooling vascular structures
BR112018013919A2 (pt) 2016-01-07 2018-12-11 Zeltiq Aesthetics Inc adesão dependente de temperatura entre o aplicador e a pele durante o resfriamento do tecido
US10765552B2 (en) 2016-02-18 2020-09-08 Zeltiq Aesthetics, Inc. Cooling cup applicators with contoured heads and liner assemblies
US10555831B2 (en) 2016-05-10 2020-02-11 Zeltiq Aesthetics, Inc. Hydrogel substances and methods of cryotherapy
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
US10682297B2 (en) 2016-05-10 2020-06-16 Zeltiq Aesthetics, Inc. Liposomes, emulsions, and methods for cryotherapy
US11076879B2 (en) 2017-04-26 2021-08-03 Zeltiq Aesthetics, Inc. Shallow surface cryotherapy applicators and related technology
CN112020354A (zh) 2018-04-26 2020-12-01 Adt制药有限责任公司 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途
WO2020028472A1 (fr) 2018-07-31 2020-02-06 Zeltiq Aesthetics, Inc. Procédés, dispositifs et systèmes pour l'amélioration d'une ou de plusieurs caractéristiques de la peau
WO2020138015A1 (fr) * 2018-12-27 2020-07-02 大正製薬株式会社 Composé macrocyclique de pyrazolo[1,5-a] pyrimidine

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3976545A (en) 1973-03-12 1976-08-24 Icn Pharmaceuticals, Inc. 1,2,4-Triazol E-3-carboxamides as antiviral agents
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
ES2088839T3 (es) 1992-12-29 1997-02-01 Abbott Lab Compuestos que inhiben las proteasas retrovirales.
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
PL360081A1 (en) 2000-07-24 2004-09-06 Bayer Cropscience Ag Biphenyl carboxamides
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
FR2834725B1 (fr) * 2002-01-15 2004-06-11 Rieter Perfojet Machine de production d'un produit textile a motifs et produit non tisse ainsi obtenu
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
RU2366655C2 (ru) 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
US20050037214A1 (en) * 2003-07-17 2005-02-17 Fish Robert B. Nylon composite articles of manufacture and processes for their preparation
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
ES2398912T3 (es) 2003-10-14 2013-03-22 F. Hoffmann-La Roche Ltd. Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C
WO2005042020A2 (fr) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Inhibiteurs combinés destinés au traitement du vhc
JP4970048B2 (ja) 2003-12-22 2012-07-04 カトリーケ・ウニフェルジテイト・ルーベン・カー・イュー・ルーベン・アール・アンド・ディ イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
JP4950026B2 (ja) 2004-03-30 2012-06-13 インターミューン・インコーポレーテッド ウイルス複製阻害剤としての大環状化合物
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
US7595340B2 (en) * 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
EP2305696A3 (fr) 2005-07-25 2011-10-12 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
US7368024B2 (en) * 2005-09-01 2008-05-06 The Goodyear Tire & Rubber Company Balanced tire assembly and method
ES2356776T3 (es) 2005-10-11 2011-04-13 Intermune, Inc. Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
SE529570C2 (sv) * 2006-01-31 2007-09-18 Cargine Engineering Ab Tvåtakts förbränningsmotor
GB0608899D0 (en) 2006-05-05 2006-06-14 Leuven K U Res & Dev Novel viral replication inhibitors
US8238259B2 (en) * 2006-07-04 2012-08-07 Hitachi, Ltd. Method for building ad hoc network
WO2008009079A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Ptéridines substituées utilisables pour le traitement et la prévention des infections virales
US20080019303A1 (en) * 2006-07-21 2008-01-24 Troicom, Inc. Adaptive resource allocation for orthogonal frequency division multiple access
WO2008019303A2 (fr) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
CN101674844A (zh) 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008154601A1 (fr) 2007-06-12 2008-12-18 Genelabs Technologies, Inc. Inhibiteurs anti-viraux et procédés d'utilisation
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US20090047247A1 (en) 2007-08-13 2009-02-19 Yao-Ling Qiu Pyrrolidine Derivatives
US20090060874A1 (en) 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8273709B2 (en) * 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
CA2715400A1 (fr) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Derives heterocycliques inhibiteurs du virus de l'hepatite c
CN101998952B (zh) 2008-02-12 2014-10-08 百时美施贵宝公司 丙型肝炎病毒抑制剂
DK2242752T3 (da) 2008-02-13 2012-11-19 Bristol Myers Squibb Co Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY31685A (es) 2008-03-04 2009-11-10 Smithkline Beecham Corp Compuestos antivirales, composiciones y metodos para usarlos
WO2010014744A1 (fr) 2008-07-29 2010-02-04 The Scripps Research Institute Inhibiteurs d'une infection par le virus de l'hépatite c
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2774927A1 (fr) 2008-12-03 2014-09-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite C de type NS5A
EP2373172B1 (fr) 2008-12-03 2013-07-17 Presidio Pharmaceuticals, Inc. Inhibiteurs de la protéine ns5a du vhc
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
EP2398474A4 (fr) 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc Inhibiteurs du ns5a du vhc
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MX2011010084A (es) 2009-03-27 2011-10-14 Merck Sharp & Dohme Inhibidores de la replicacion del virus de la hepatitis c.
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
AU2010240882B2 (en) 2009-04-24 2014-10-23 Janssen Sciences Ireland Uc Diaryl ethers
US8414436B2 (en) * 2009-04-30 2013-04-09 GM Global Technology Operations LLC Hybrid powertrain and method of operating same
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
TW201503888A (zh) 2009-05-13 2015-02-01 Gilead Sciences Inc 抗病毒化合物
CA2762885A1 (fr) 2009-05-29 2010-12-02 Schering Corporation Composes antiviraux constitues de trois fractions d'aryle alignees pour traiter des maladies telles que l'hepatite c
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8545161B2 (en) * 2009-05-29 2013-10-01 Peter WANEK-PUSSET Unloading vehicle and combination of an unloading vehicle with a container
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2628481T3 (pl) 2009-06-11 2016-08-31 Abbvie Bahamas Ltd Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C
WO2010148006A1 (fr) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (fr) 2009-07-06 2011-01-13 Pfizer Limited Inhibiteurs du virus de l’hépatite c
CN102656160A (zh) 2009-07-16 2012-09-05 顶点制药公司 用于治疗或预防黄病毒感染的苯并咪唑类似物
AU2010280711A1 (en) 2009-08-07 2012-02-09 Janssen Sciences Ireland Uc Phenyl ethynyl derivatives as hepatitis C virus inhibitors
EP2462135A1 (fr) 2009-08-07 2012-06-13 Janssen R&D Ireland Dérivés de bis-benzimidazole en tant qu'inhibiteurs du virus de l'hépatite c
CN102482260A (zh) 2009-09-03 2012-05-30 泰博特克药品公司 双-苯并咪唑衍生物
CA2771327A1 (fr) 2009-09-04 2011-03-10 Glaxosmithkline Llc Composes chimiques
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031904A1 (fr) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Inhibiteurs du virus de l'hépatite c
EP2475254A4 (fr) 2009-09-11 2013-05-22 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (fr) 2009-10-23 2011-04-28 Glaxosmithkline Llc Composés chimiques
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
AU2010347272A1 (en) * 2010-03-04 2012-09-20 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
WO2011127350A1 (fr) * 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c

Also Published As

Publication number Publication date
AU2011207492A1 (en) 2012-08-16
KR20120107529A (ko) 2012-10-02
IL221033A0 (en) 2012-09-24
JP2013518060A (ja) 2013-05-20
WO2011091417A1 (fr) 2011-07-28
BR112012018529A2 (pt) 2016-08-09
CU20120110A7 (es) 2012-12-17
CN102843909A (zh) 2012-12-26
PE20130244A1 (es) 2013-03-10
EP2528436A4 (fr) 2013-07-10
GT201200230A (es) 2015-06-02
US20110189129A1 (en) 2011-08-04
ECSP12012067A (es) 2012-12-28
CR20120397A (es) 2013-05-15
EP2528436A1 (fr) 2012-12-05
TN2012000358A1 (en) 2014-01-30
EA201201031A1 (ru) 2013-02-28
US8785487B2 (en) 2014-07-22
MX2012008658A (es) 2012-12-05
CO6571891A2 (es) 2012-11-30
CL2012002057A1 (es) 2013-05-10
SG188957A1 (en) 2013-05-31
CA2787309A1 (fr) 2011-07-28

Similar Documents

Publication Publication Date Title
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
WO2008021871A3 (fr) Inhibiteurs triazolyle acyclique de la sérine protéase de l'hépatite c
WO2008022006A3 (fr) Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle
MY155851A (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
WO2008021956A3 (fr) Inhibiteurs d'acylamino-hétéroaryle de la protéase du virus de l'hépatite c
WO2009076166A3 (fr) Inhibiteurs oximyles de la sérine protéase de vhc
MX2010006209A (es) Derivados de quinoxalinilo.
WO2008019266A3 (fr) Inhibiteurs de sérine protéase de l'hépatite c dérivés de pyridazinone acycliques
WO2008021960A3 (fr) Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c
WO2008021733A3 (fr) Inhibiteurs acycliques tétrazolylés de la sérine protéase de l'hépaptite c
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
WO2009053828A3 (fr) Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c
WO2007143694A3 (fr) Inhibiteurs oximyles macrocycliques de la protéase de l'hépatite c
EP2555622A4 (fr) Inhibiteurs du virus de l'hépatite c
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
MA32225B1 (fr) Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c
MX2010005261A (es) Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
CA2753382C (fr) Inhibiteurs du virus de l'hepatite c
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
WO2008019303A3 (fr) Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
WO2008002924A3 (fr) Inhibiteurs macrocycliques quinoxalinyliques des protéases à sérine du virus de l'hépatite c
WO2009085978A8 (fr) Inhibiteurs de protéase de sérine de virus de l'hépatite c d'oxime carbocyclique couronnés